National Health Research Institutes (NHRI) and AnBogen Therapeutics Inc. (AnBogen) signed a technology transfer agreement in January 2025. Under this agreement, AnBogen has obtained the exclusive rights to DBPR376, a novel small-molecule Mertansine conjugate targeting luteinizing hormone-releasing hormone receptor (LHRHR), with global patents.
About DBPR376
DBPR376 is a new peptide drug conjugate designed for precise cancer therapy. Using a modified LHRH peptide antagonist, it selectively binds to LHRHR, which is overexpressed in various cancers but minimally present in normal tissues. Coupled with a patented linker-mertansine module, it enables targeted drug delivery, demonstrating potent efficacy in TNBC and ovarian cancer models. Tumor-associated LHRHR also serves as a biomarker for patient selection, supporting its potential in precision oncology and theranostics.
About AnBogen Therapeutics
AnBogen Therapeutics Inc. is a clinical-stage biotech company dedicated to designing and developing precision oncology therapies to improve patients’ lives. Founded by a group of exceptional scientists committed to bridging the gap between research and clinical development. Anbogen’s mission is to create breakthrough science that transforms the lives of cancer patients. For more information, visit https://anbogen.com/en/.
About IBPR at NHRI
The Institute of Biotechnology and Pharmaceutical Research at NHRI is a mission-driven drug discovery and development engine, integrating vertical and horizontal expertise to advance innovative therapies. For more information, visit https://ibpr.nhri.edu.tw/en/.